Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy
Open Access
- 24 July 2012
- journal article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 14 (4) , R172
Abstract
Introduction: Sjögren's syndrome (SjS) is a systemic autoimmune disease characterized by decreased salivary and lacrimal gland secretions, resulting in severe dry mouth and dry eyes. Recent studies have suggested that TH17 cells and its signature cytokine IL-17 are involved in the underlying pathogenic mechanisms leading to destructive inflammation and autoimmunity. In the present study, we examined whether IL-27, a natural inhibitor of TH17 activity, could down-regulate or reverse SjS in C57BL/6.NOD-Aec1Aec2 mice, a model of primary-SjS. Methods: Recombinant serotype 2 adeno-associated viral (AAV2) vectors expressing either IL-27 (rAAV2-IL27) or LacZ (rAAV2-LacZ) were injected into 6 or 14 week-old C57BL/6.NOD-Aec1Aec2 mice. Changes in IL-27, IL-17, and IL-10 cytokine levels in peripheral blood were determined by ELISAs, while flow cytometry analyses were used to quantify cytokine-positive splenocytes. Histological assessment of salivary glands, anti-nuclear autoantibody (ANA) staining, and stimulated saliva flow rates were used to profile SjS disease severity. Results: Mice systemically treated with intravenous rAAV2-IL27 injections at either 6 or 14 weeks of age exhibited long-term elevated levels of serum IL-27 with concomitantly reduced levels of IL-17 compared with sera from mice injected with rAAV2-LacZ or saline out to 20 weeks post-inoculation. Most importantly, disease profiles revealed that rAAV2-IL27 treatment had little effect on lymphocytic focus (LF) scores, but resulted in structural changes in LF, lower titers of ANAs with changes in staining patterns, and a less severe clinical disease as determined by saliva flow rates. Conclusions: These data support the concept that IL-27, when provided exogenously, can induce a suppressive effect on SjS development and thus may be an effective therapeutic agent for regulating TH17 pro-inflammatory activity in autoimmune diseases where the TH17 system has been shown to play an important role in their pathogenesis.Keywords
This publication has 63 references indexed in Scilit:
- Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-γ limits IL-17–mediated autoimmune inflammationProceedings of the National Academy of Sciences, 2010
- Therapeutic potential of IL-27 in systemic lupus erythematosusExpert Opinion on Therapeutic Targets, 2010
- Antitumor Activities of Interleukin-27 on MelanomaEndocrine, Metabolic & Immune Disorders - Drug Targets, 2010
- IL-12 and IL-27 Sequential Gene Therapy via Intramuscular Electroporation Delivery for Eliminating Distal Aggressive TumorsThe Journal of Immunology, 2010
- Primary non-Hodgkin′s lymphoma of the salivary gland: A spectrum of lymphoepithelial sialadenitis, low-grade B-cell lymphoma of mucosa-associated lymphoid tissue with transformation to high-grade lymphomaIndian Journal of Pathology and Microbiology, 2010
- IL-27 Directly Restrains Lung Tumorigenicity by Suppressing Cyclooxygenase-2-Mediated ActivitiesThe Journal of Immunology, 2009
- Interleukin-27 inhibition of HIV-1 involves an intermediate induction of type I interferonBlood, 2009
- Improved Method of Recombinant AAV2 Delivery for Systemic Targeted Gene TherapyMolecular Therapy, 2002
- Clinical and immunological factors associated with low lacrimal and salivary flow rate in patients with primary Sjögren's syndrome.2002
- Safety and Biological Efficacy of an Adeno‐Associated Virus Vector–Cystic Fibrosis Transmembrane Regulator (AAV‐CFTR) in the Cystic Fibrosis Maxillary SinusThe Laryngoscope, 1999